Table 1. An excess in polar cell number is produced in egg chambers upon overexpression of the baculovirus caspase inhibitor p35 in these cells.

	Stage 3		Stage 4		Stages 5–6		Stages 7–8		Stages 9–10		Stages 7–10
Genotype	A	P	A	P	A	P	A	P	A	P	(A+P)
	n=51		n=48		n=71		n=50		n=60		n=220
upd-gal4/+ UAS-mCD8:GFP/+
Chambers with two PCs (%)	78	67	100	98	100	100	100	100	100	100	100
Chambers with three PCs (%)	20	33	0	2	0	0	0	0	0	0	0
Chambers with four PCs (%)	2	0	0	0	0	0	0	0	0	0	0
Average nb of PCs	2.2	2.4	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
	n=49		n=21		n=45		n=40		n=23		n=126
upd-gal4/+UAS-p35/UAS-mCD8:GFP
Chambers with two PCs (%)	21	57	29	24	38	36	30	30	27	45	32
Chambers with three PCs (%)	73	37	62	62	53	55	55	55	73	55	58
Chambers with four PCs (%)	6	6	9	14	7	7	15	13	0	0	8
Chambers with five PCs (%)	0	0	0	0	2	0	0	2	0	0	1
Chambers with six PCs (%)	0	0	0	0	0	2	0	0	0	0	1
Average nb of PCs	2.9	2.5	2.8	2.9	2.7	2.8	2.8	2.8	2.7	2.5	2.7

In females ectopically expressing the baculovirus caspase inhibitor p35 specifically in polar cells, the number of polar cells (PCs), as indicated by Fas3 immunostaining, both at the anterior (A) and posterior (P) ends of each chamber, was determined from stages 3 to 10 of oogenesis. Results are expressed as the percentage of total chambers (n) of a given genotype with 2, 3, 4, 5 or 6 polar cells. The average number of polar cells at each pole for each stage is indicated at the bottom of each column